Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250011/S006

ProVee System for BPH

Proverum, Ltd. · Decision date Sep 24, 2026

MEDTECHLEDGER EXPLANATIONP250011/S006

What did the FDA approve?

The FDA record lists P250011/S006 for the ProVee System as an approved special (immediate track) supplement, dated 2026-09-24, with reason 'Process Change - Manufacturer/Sterilizer/Packager/Supplier.' The source statement describes 'the addition of a step to the ProVee System's final assembly process.' That is the full extent of the described change; the record does not name the added step, its equipment, controls or validation, so the technical scope beyond final assembly cannot be explained from these fields.

The S006 identifier places this action as a supplement to PMA P250011, not a new approval of the ProVee System as a whole. The device category for the parent filing is a permanent or semi-permanent prostatic or urethral stent, product code MER, sponsored by Proverum, Ltd. The stated purpose concerns a manufacturing process addition; the record itself is not independent proof of safety or clinical effectiveness and adds no indication or trial information.

FDA approval order statement

the addition of a step to the ProVee Systems final assembly process.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 24, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250011/S006
Regulatory pathway
PMA supplement
Product code
MER
Decision code
APPR
Decision date
Sep 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.

Product code
MER
FDA device class
3

For the original device and its historical approval scope, see PMA P250011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250011 · Original PMA

    ProVee System for BPH

  2. P250011/S006 received

    Application receipt date recorded by FDA.

  3. P250011/S006 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250011

Product / regulatory recordCompanyPathwayDecision dateSource
Proverum, Ltd.PMA approvalDec 9, 2025FDA
Proverum, Ltd.PMA supplementNov 3, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Proverum, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records